Introduction – Company Background

GuangXin Industrial Co., Ltd. is a specialized manufacturer dedicated to the development and production of high-quality insoles.

With a strong foundation in material science and footwear ergonomics, we serve as a trusted partner for global brands seeking reliable insole solutions that combine comfort, functionality, and design.

With years of experience in insole production and OEM/ODM services, GuangXin has successfully supported a wide range of clients across various industries—including sportswear, health & wellness, orthopedic care, and daily footwear.

From initial prototyping to mass production, we provide comprehensive support tailored to each client’s market and application needs.

At GuangXin, we are committed to quality, innovation, and sustainable development. Every insole we produce reflects our dedication to precision craftsmanship, forward-thinking design, and ESG-driven practices.

By integrating eco-friendly materials, clean production processes, and responsible sourcing, we help our partners meet both market demand and environmental goals.

Core Strengths in Insole Manufacturing

At GuangXin Industrial, our core strength lies in our deep expertise and versatility in insole and pillow manufacturing. We specialize in working with a wide range of materials, including PU (polyurethane), natural latex, and advanced graphene composites, to develop insoles and pillows that meet diverse performance, comfort, and health-support needs.

Whether it's cushioning, support, breathability, or antibacterial function, we tailor material selection to the exact requirements of each project-whether for foot wellness or ergonomic sleep products.

We provide end-to-end manufacturing capabilities under one roof—covering every stage from material sourcing and foaming, to precision molding, lamination, cutting, sewing, and strict quality control. This full-process control not only ensures product consistency and durability, but also allows for faster lead times and better customization flexibility.

With our flexible production capacity, we accommodate both small batch custom orders and high-volume mass production with equal efficiency. Whether you're a startup launching your first insole or pillow line, or a global brand scaling up to meet market demand, GuangXin is equipped to deliver reliable OEM/ODM solutions that grow with your business.

Customization & OEM/ODM Flexibility

GuangXin offers exceptional flexibility in customization and OEM/ODM services, empowering our partners to create insole products that truly align with their brand identity and target market. We develop insoles tailored to specific foot shapes, end-user needs, and regional market preferences, ensuring optimal fit and functionality.

Our team supports comprehensive branding solutions, including logo printing, custom packaging, and product integration support for marketing campaigns. Whether you're launching a new product line or upgrading an existing one, we help your vision come to life with attention to detail and consistent brand presentation.

With fast prototyping services and efficient lead times, GuangXin helps reduce your time-to-market and respond quickly to evolving trends or seasonal demands. From concept to final production, we offer agile support that keeps you ahead of the competition.

Quality Assurance & Certifications

Quality is at the heart of everything we do. GuangXin implements a rigorous quality control system at every stage of production—ensuring that each insole meets the highest standards of consistency, comfort, and durability.

We provide a variety of in-house and third-party testing options, including antibacterial performance, odor control, durability testing, and eco-safety verification, to meet the specific needs of our clients and markets.

Our products are fully compliant with international safety and environmental standards, such as REACH, RoHS, and other applicable export regulations. This ensures seamless entry into global markets while supporting your ESG and product safety commitments.

ESG-Oriented Sustainable Production

At GuangXin Industrial, we are committed to integrating ESG (Environmental, Social, and Governance) values into every step of our manufacturing process. We actively pursue eco-conscious practices by utilizing eco-friendly materials and adopting low-carbon production methods to reduce environmental impact.

To support circular economy goals, we offer recycled and upcycled material options, including innovative applications such as recycled glass and repurposed LCD panel glass. These materials are processed using advanced techniques to retain performance while reducing waste—contributing to a more sustainable supply chain.

We also work closely with our partners to support their ESG compliance and sustainability reporting needs, providing documentation, traceability, and material data upon request. Whether you're aiming to meet corporate sustainability targets or align with global green regulations, GuangXin is your trusted manufacturing ally in building a better, greener future.

Let’s Build Your Next Insole Success Together

Looking for a reliable insole manufacturing partner that understands customization, quality, and flexibility? GuangXin Industrial Co., Ltd. specializes in high-performance insole production, offering tailored solutions for brands across the globe. Whether you're launching a new insole collection or expanding your existing product line, we provide OEM/ODM services built around your unique design and performance goals.

From small-batch custom orders to full-scale mass production, our flexible insole manufacturing capabilities adapt to your business needs. With expertise in PU, latex, and graphene insole materials, we turn ideas into functional, comfortable, and market-ready insoles that deliver value.

Contact us today to discuss your next insole project. Let GuangXin help you create custom insoles that stand out, perform better, and reflect your brand’s commitment to comfort, quality, and sustainability.

🔗 Learn more or get in touch:
🌐 Website: https://www.deryou-tw.com/
📧 Email: shela.a9119@msa.hinet.net
📘 Facebook: facebook.com/deryou.tw
📷 Instagram: instagram.com/deryou.tw

Indonesia insole ODM design and production

Are you looking for a trusted and experienced manufacturing partner that can bring your comfort-focused product ideas to life? GuangXin Industrial Co., Ltd. is your ideal OEM/ODM supplier, specializing in insole production, pillow manufacturing, and advanced graphene product design.

With decades of experience in insole OEM/ODM, we provide full-service manufacturing—from PU and latex to cutting-edge graphene-infused insoles—customized to meet your performance, support, and breathability requirements. Our production process is vertically integrated, covering everything from material sourcing and foaming to molding, cutting, and strict quality control.ESG-compliant OEM manufacturer in Taiwan

Beyond insoles, GuangXin also offers pillow OEM/ODM services with a focus on ergonomic comfort and functional innovation. Whether you need memory foam, latex, or smart material integration for neck and sleep support, we deliver tailor-made solutions that reflect your brand’s values.

We are especially proud to lead the way in ESG-driven insole development. Through the use of recycled materials—such as repurposed LCD glass—and low-carbon production processes, we help our partners meet sustainability goals without compromising product quality. Our ESG insole solutions are designed not only for comfort but also for compliance with global environmental standards.Graphene insole manufacturer in China

At GuangXin, we don’t just manufacture products—we create long-term value for your brand. Whether you're developing your first product line or scaling up globally, our flexible production capabilities and collaborative approach will help you go further, faster.Indonesia custom insole OEM supplier

📩 Contact us today to learn how our insole OEM, pillow ODM, and graphene product design services can elevate your product offering—while aligning with the sustainability expectations of modern consumers.ODM service for ergonomic pillows Taiwan

Salk scientists developed a technique of using sound waves to control brain cells, dubbed sonogenetics, to selectively and noninvasively turn on groups of neurons. It was first used on worms and now has been used on mammalian cells. This technique could be a boon to science and medicine. Credit: Courtesy of the Salk Institute for Biological Studies Salk researchers pinpoint a sound-sensitive mammalian protein that lets them activate brain, heart or other cells with ultrasound. Salk scientists have engineered mammalian cells to be activated using ultrasound. The method, which the team used to activate human cells in a dish and brain cells inside living mice, paves the way toward non-invasive versions of deep brain stimulation, pacemakers and insulin pumps. The findings will be published in Nature Communications today (February 9, 2022). “Going wireless is the future for just about everything,” says senior author Sreekanth Chalasani, an associate professor in Salk’s Molecular Neurobiology Laboratory. “We already know that ultrasound is safe, and that it can go through bone, muscle, and other tissues, making it the ultimate tool for manipulating cells deep in the body.” Challenges and Discoveries in Protein Screening About a decade ago, Chalasani pioneered the idea of using ultrasonic waves to stimulate specific groups of genetically marked cells, and coined the term “sonogenetics” to describe it. In 2015, his group showed that, in the roundworm Caenorhabditis elegans, a protein called TRP-4 makes cells sensitive to low-frequency ultrasound. When the researchers added TRP-4 to C. elegans neurons that didn’t usually have it, they could activate these cells with a burst of ultrasound—the same sound waves used in medical sonograms. Neurons (magenta) in the mouse brain. The Chalasani lab made specific neurons express TRPA1 (white), so they can be activated by ultrasound. Credit: Salk Institute When the researchers tried adding TRP-4 to mammalian cells, however, the protein was not able to make the cells respond to ultrasound. A few mammalian proteins were reported to be ultrasound-sensitive, but none seemed ideal for clinical use. So Chalasani and his colleagues set out to search for a new mammalian protein that made cells highly ultrasound sensitive at 7 MHz, considered an optimal and safe frequency. “Our approach was different than previous screens because we set out to look for ultrasound-sensitive channels in a comprehensive way,” says Yusuf Tufail, a former project scientist at Salk and a co-first author of the new paper. TRPA1 Protein The researchers added hundreds of different proteins, one at a time, to a common human research cell line (HEK), which does not usually respond to ultrasound. Then, they put each cell culture under a setup that let them monitor changes to the cells upon ultrasound stimulation. Top from left: Sreekanth Chalasani and Corinne Lee-Kubli. Bottom from left: Marc Duque and Yusuf Tufail. Credit: Top: Salk Institute. Bottom from left: Marc Duque and Yusuf Tufail After screening proteins for more than a year, and working their way through nearly 300 candidates, the scientists finally found one that made the HEK cells sensitive to the 7 MHz ultrasound frequency. TRPA1, a channel protein, was known to let cells respond to the presence of noxious compounds and to activate a range of cells in the human body, including brain and heart cells. But Chalasani’s team discovered that the channel also opened in response to ultrasound in HEK cells. “We were really surprised,” says co-first author of the paper Marc Duque, a Salk exchange student. “TRPA1 has been well-studied in the literature but hasn’t been described as a classical mechanosensitive protein that you’d expect to respond to ultrasound.” To test whether the channel could activate other cell types in response to ultrasound, the team used a gene therapy approach to add the genes for human TRPA1 to a specific group of neurons in the brains of living mice. When they then administered ultrasound to the mice, only the neurons with the TRPA1 genes were activated. Expanding Sonogenetics Applications Beyond the Lab Clinicians treating conditions including Parkinson’s disease and epilepsy currently use deep brain stimulation, which involves surgically implanting electrodes in the brain, to activate certain subsets of neurons. Chalasani says that sonogenetics could one day replace this approach—the next step would be developing a gene therapy delivery method that can cross the blood-brain barrier, something that is already being studied. Perhaps sooner, he says, sonogenetics could be used to activate cells in the heart, as a kind of pacemaker that requires no implantation. “Gene delivery techniques already exist for getting a new gene—such as TRPA1—into the human heart,” Chalasani says. “If we can then use an external ultrasound device to activate those cells, that could really revolutionize pacemakers.” For now, his team is carrying out more basic work on exactly how TRPA1 senses ultrasound. “In order to make this finding more useful for future research and clinical applications, we hope to determine exactly what parts of TRPA1 contribute to its ultrasound sensitivity and tweak them to enhance this sensitivity,” says Corinne Lee-Kubli, a co-first author of the paper and former postdoctoral fellow at Salk. They also plan to carry out another screen for ultrasound sensitive proteins—this time looking for proteins that can inhibit, or shut off, a cell’s activity in response to ultrasound. Reference: “Sonogenetic control of mammalian cells using exogenous Transient Receptor Potential A1 channels” by Marc Duque, Corinne A. Lee-Kubli, Yusuf Tufail, Uri Magaram, Janki Patel, Ahana Chakraborty, Jose Mendoza Lopez, Eric Edsinger, Aditya Vasan, Rani Shiao, Connor Weiss, James Friend and Sreekanth H. Chalasani, 9 February 2022, Nature Communications. DOI: 10.1038/s41467-022-28205-y The other authors of the paper were Uri Magaram, Janki Patel, Ahana Chakraborty, Jose Mendoza Lopez, Eric Edsinger, Rani Shiao and Connor Weiss of Salk; and Aditya Vasan and James Friend of UC San Diego. The work was supported by the National Institutes of Health (R01MH111534, R01NS115591), Brain Research Foundation, Kavli Institute of Brain and Mind, Life Sciences Research Foundation, W.M. Keck Foundation (SERF), and the Waitt Advanced Biophotonics and GT3 Cores (which receive funding through NCI CCSG P30014195 and NINDSR24).

The mouse atrioventricular (AV) node. Green staining indicates AV node cells, while red staining highlights neighboring atrial muscle cells. All cell nuclei are stained blue. Credit: UT Southwestern Medical Center Specialized cells that propagate heartbeats have the capacity to regenerate after birth, study by UT Southwestern scientists shows. Specialized cells that conduct electricity to keep the heart beating have a previously unrecognized ability to regenerate in the days after birth, a new study in mice by UT Southwestern researchers suggests. The finding, published online in the Journal of Clinical Investigation, could eventually lead to treatments for heart rhythm disorders that avoid the need for invasive pacemakers or drugs by instead encouraging the heart to heal itself. “Patients with arrhythmias don’t have a lot of great options,” said study leader Nikhil V. Munshi, M.D., Ph.D., a cardiologist and Associate Professor of Internal Medicine, Molecular Biology, and in the Eugene McDermott Center for Human Growth and Development. “Our findings suggest that someday we may be able to elicit regeneration from the heart itself to treat these conditions.” Nikhil V. Munshi, M.D., Ph.D. Credit: UT Southwestern Medical Center Dr. Munshi studies the cardiac conduction system, an interconnected system of specialized heart muscle cells that generate electrical impulses and transmit these impulses to make the heart beat. Although studies have shown that nonconducting heart muscle cells have some regenerative capacity for a limited time after birth – with many discoveries in this field led by UTSW scientists – conducting cells called nodal cells were largely thought to lose this ability during the fetal period. Previous research had suggested that neonatal nodal cells lose stem cell-like qualities before birth, giving them negligible regenerative properties. However, Dr. Munshi explained, their regenerative abilities had never been directly tested because there was no way to eliminate only nodal cells in animal models to spur regeneration. To solve this problem, Dr. Munshi and his colleagues used genetic engineering to develop mice whose atrioventricular (AV) node cells, located near the intersection of the heart’s four chambers, died when they were fed the breast cancer drug tamoxifen. In adult mice of this strain that were given tamoxifen, tissue samples and electrocardiograms revealed progressive heart damage stemming from the death of AV node cells in the following weeks and months. However, when neonatal mice were dosed, heart function appeared to be completely normal in one-third of the animals about a month later. Taking a closer look, the researchers performed electrocardiograms on newborn mouse models of AV node failure every couple of days after tamoxifen treatment. These tests revealed an initial injury to the heart that gradually healed itself in many of the animals. Although tissue examination showed that this healing didn’t result in a completely normal heart in adulthood, it was sufficient for the mice to have regular heart rhythms. Intriguingly, further investigation showed that nonmuscle heart cells were the predominant cell type that proliferated after the nodal cells died. These cells appeared to modulate production of proteins that help heart cells make electrical connections. Why these proteins increased and why only about one-third of the animals showed regeneration remain unclear, Dr. Munshi said. He and his colleagues plan to continue studying the molecular mechanisms behind this phenomenon to gain more knowledge that could eventually lead to a drug that can stimulate the regeneration pathway on demand to regrow damaged nodes in arrhythmia patients. Reference: “Inducible cardiomyocyte injury within the atrioventricular conduction system uncovers latent regenerative capacity in mice” by Lin Wang, Minoti Bhakta, Antonio Fernandez-Perez and Nikhil V. Munshi, 1 October 2021, Journal of Clinical Investigation. DOI: 10.1172/JCI138637 Other UTSW scientists who contributed to this study include Lin Wang, Minoti Bhakta, and Antonio Fernandez-Perez. This work was supported by grants from the National Institutes of Health (HL136604, HL133642, and HL135217), the Burroughs Wellcome Fund (1009838), and the March of Dimes Foundation (#5-FY13-203).

According to a new study by Northwestern Medicine, neurons in an area of the brain responsible for memory were significantly larger in SuperAgers compared to cognitively average peers. Post-mortem brains of SuperAgers reveal significantly larger neurons in memory region. SuperAger neurons are even larger than those in individuals 20 to 30 years younger These neurons do not have tau tangles that are a hallmark of Alzheimer’s Larger neurons in the brain’s memory region are a biological signature of SuperAging trajectory Neurons in the entorhinal cortex, an area of the brain responsible for memory, were significantly larger in SuperAgers compared to cognitively average peers and individuals with early-stage Alzheimer’s disease. They were even larger compared to individuals 20 to 30 years younger than SuperAgers — who are aged 80 years and older. This is all according to a new Northwestern Medicine study that was published on September 30 in The Journal of Neuroscience. Unique Biological Signature of SuperAgers These SuperAger neurons did not harbor tau tangles, a signature hallmark of Alzheimer’s disease. “The remarkable observation that SuperAgers showed larger neurons than their younger peers may imply that large cells were present from birth and are maintained structurally throughout their lives,” said lead author Tamar Gefen. She is an assistant professor of psychiatry and behavioral sciences at Northwestern University Feinberg School of Medicine. “We conclude that larger neurons are a biological signature of the SuperAging trajectory.”   The study of SuperAgers with exceptional memory was the first research to demonstrate that these individuals carry a unique biological signature that comprises larger and healthier neurons in the entorhinal cortex that are relatively void of tau tangles (pathology). The Northwestern SuperAging Research Program studies unique individuals known as SuperAgers, 80+ year-olds who show extraordinary memory at least as good as individuals 20 to 30 years their junior.  “To understand how and why people may be resistant to developing Alzheimer’s disease, it is important to closely investigate the postmortem brains of SuperAgers,” Gefen said. “What makes SuperAgers’ brains unique? How can we harness their biologic traits to help elderly stave off Alzheimer’s disease?”   Researchers investigated the entorhinal cortex of the brain because it controls memory and is one of the first locations targeted by Alzheimer’s disease. The entorhinal cortex is comprised of six layers of neurons packed on top of one another. Layer II, in particular, receives information from other memory centers and is a very specific and crucial hub along the brain’s memory circuit.   In the study, the research team demonstrated that SuperAgers harbor large, healthier neurons in layer II of the entorhinal cortex compared to their same-aged peers, people with early stages of Alzheimer’s disease, and even individuals 20 to 30 years younger. They also found that these large layer II neurons were spared from the formation of tau tangles.   Link Between Tau Tangles and Neuronal Shrinkage Taken together, the findings indicate that a neuron spared from tangle formation can maintain its structural integrity (i.e., remain healthy and large). The inverse also appears to be true: Tau tangles can lead to neuronal shrinkage.  Participants in the SuperAger study donate their brains for research after their death.  For the study, researchers analyzed the brains of six SuperAgers, seven cognitively average elderly individuals, six young individuals, and five individuals with early stages of Alzheimer’s. They measured the size of neurons in layer II of the entorhinal cortex (compared to layers III and V) of all the brains. They also assessed the presence of tau tangles in these cases.  For reasons that remain unknown, cell populations in the entorhinal cortex are selectively vulnerable to tau tangle formation during normal aging and in the early stages of Alzheimer’s disease.  “In this study, we show that in Alzheimer’s, neuronal shrinkage (atrophy) in the entorhinal cortex appears to be a characteristic marker of the disease,” Gefen said.  “We suspect this process is a function of tau tangle formation in the affected cells leading to poor memory abilities in older age,” Gefen said. “Identifying this contributing factor (and every contributing factor) is crucial to the early identification of Alzheimer’s, monitoring its course and guiding treatment.”  Future research is necessary to determine how and why neuronal integrity is preserved in SuperAgers. Gefen wants to specifically focus on probing the cellular environment.  “What are the chemical, metabolic or genetic features of these cells that render them resilient?” she asked. She also plans to investigate other hubs along the memory circuit of the brain to better understand the spread of or resistance to disease.  “We expect this research to be amplified and more impactful through a $20 million expansion of the SuperAging Initiative now enrolling five sites in the U.S. and Canada,” said Emily Rogalski. She is the associate director of the Mesulam Center for Cognitive Neurology and Alzheimer’s Disease at Northwestern University Feinberg School of Medicine. Reference: “Integrity of neuronal size in the entorhinal cortex is a biologic substrate of exceptional cognitive aging” by Caren Nassif, Allegra Kawles, Ivan Ayala, Grace Minogue, Nathan P. Gill, Robert A. Shepard, Antonia Zouridakis, Rachel Keszycki, Hui Zhang, Qinwen Mao [MD, PhD], Margaret E. Flanagan [MD], Eileen H. Bigio [MD], M.-Marsel Mesulam [MD], Emily Rogalski [PhD], Changiz Geula [PhD] and Tamar Gefen [PhD], 30 September 2022, The Journal of Neuroscience. DOI: 10.1523/JNEUROSCI.0679-22.2022 This study was supported by the National Institute on Aging of the National Institutes of Health (grant numbers P30AG013854, R01AG062566, R01AG067781, R01AG045571, R56AG045571, and U19AG073153).

DVDV1551RTWW78V